Win For AZ's COPD Triple Combo In Bid To Catch GSK
Executive Summary
GlaxoSmithKline is streets ahead in the three-in-one COPD market, having received approval last year in the USA and Europe for Trelegy Ellipta, but AstraZeneca's PT010 may provide competition in the future having met six out of seven lung function primary endpoints in a Phase III trial.
You may also be interested in...
AstraZeneca’s COPD Triple Combo Drug Succeeds in ETHOS Phase III, Setting Up GSK Showdown
The triple-combination treatment significantly reduced COPD exacerbations compared to older dual therapies in the Phase III ETHOS study, providing a boost to AstraZeneca as it closes in on approvals in the US and Europe.
Novartis CEO: Oncology Treatment Almost Back To Pre-COVID Levels
The Swiss major's oncology business performed well in the third quarter with Kisqali sales catching the eye despite the specific problems that the pandemic has brought for breast cancer patients.
Cosentyx And Entresto Keep Powering Novartis As Firm Mulls Sandoz Sale
CEO Vas Narasimhan sees Novartis very much as an innovative company so the long-awaited strategic review of Sandoz suggests that the generics/biosimilars business could be spun off or sold fairly soon.